Search Results - Sha Klabunde
- Showing 1 - 1 results of 1
-
1
A phase I, randomized, ascending‐dose study to assess safety, pharmacokinetics, and activity of GDC‐8264, a RIP1 inhibitor, in healthy volunteers by Nicholas S. Jones, Smita Kshirsagar, Vishnu Mohanan, Vidya Ramakrishnan, Flavia Di Nucci, Ling Ma, Jialin Mao, Hao Ding, Sha Klabunde, Domagoj Vucic, Lin Pan, Annemarie N. Lekkerkerker, Yuan Chen, Michael E. Rothenberg
Published in Clinical and Translational Science (2023-10-01)Get full text
Article